Nanotechnology Now - Press Release: "Realizing the promise of RNA nanotechnology for new drug development"

Home > Press > Realizing the promise of RNA nanotechnology for new drug development

Nucleic Acid Therapeutics is published six times per year in print and online. For more information visit www.liebertpub.com/nat.

Credit: Š2012 Mary Ann Liebert, Inc., publishers

Nucleic Acid Therapeutics is published six times per year in print and online. For more information visit www.liebertpub.com/nat.

Credit: Š2012 Mary Ann Liebert, Inc., publishers

Abstract:
The use of RNA in nanotechnology applications is highly promising for many applications, including the development of new therapeutic compounds. Key technical challenges remain, though, and the challenges and opportunities associated with the use of RNA molecules in nanotechnology approaches are presented in a review article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. The article is available free online at the Nucleic Acid Therapeutics website.

Realizing the promise of RNA nanotechnology for new drug development

New Rochelle, NY | Posted on September 5th, 2012

Peixuan Guo and colleagues, University of Kentucky, Lexington, highlight the ability of RNA to self-assemble into nanoparticles with diverse structures. In "Uniqueness, Advantages, Challenges, Solutions, and Perspectives in Therapeutics Applying RNA Nanotechnology," the authors provide a detailed description of the main challenges faced by the RNA therapeutics industry, including the chemical and thermodynamic instability of the molecules, potential safety and side effect issues, difficulties in delivery and specific targeting, and low yield and high production costs in manufacturing.

"The remarkable structural and enzymatic properties of RNA continue to astound us," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "It is exciting to see those properties increasingly realized for the benefit of human health and welfare, as described by Dr. Guo and his colleagues."

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD, SomaLogic, Boulder, CO.

####

About Mary Ann Liebert, Inc./Genetic Engineering News
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and Human Gene Therapy Methods, Genetic Testing and Molecular Biomarkers, ASSAY and Drug Development Technologies, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website. www.liebertpub.com

About the Journal

Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a free sample issue may be viewed online at the Nucleic Acid Therapeutics website.

For more information, please click here

Contacts:
Vicki Cohn

914-740-2100 x2156

Mary Ann Liebert, Inc.
140 Huguenot St.
New Rochelle, NY 10801-5215
Phone: (914) 740-2100
(800) M-LIEBERT
Fax: (914) 740-2101
www.liebertpub.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: